MedTrace Logo

Interstitial Fluid in the Development of Cardiovascular Disease

NCT03386097 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-09-09

No results posted yet for this study

Summary

At a given level of serum cholesterol, patients with T2D have an increased risk of developing atherosclerosis compared with nondiabetic subjects.

In a previous study we showed that the interstitial fluid-to-serum gradient of LDL and VLDL cholesterol is reduced in T2D patients compared with healthy controls. This was not found for HDL cholesterol. However, the cholesterol transporting function of HDL particles from interstitial fluid from patients with T2D were lower than in healthy controls. We hypothesize that that the apo B-containing particles in T2D patients are more susceptible to be retained or consumed in the extravascular space.

We are to study if skin biopsies from T2D patients contain more cholesterol than biopsies from healthy controls. We hypothesize that samples from T2D patients are richer in cholesterol, which could explain why VLDL and LDL cholesterol are lower in relation to their plasma levels in T2D.

Conditions

Interventions

OTHER

Collection of interstitial fluid, skin biopsies and blood

Collection of interstitial fluid, skin biopsies and blood

Sponsors & Collaborators

Principal Investigators

  • Mats Rudling · Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-10
Primary Completion
2021-09-03
Completion
2021-09-03

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03386097 on ClinicalTrials.gov